Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Phil McEwanOliver DarlingtonRyan MillerJohn J V McMurrayDavid C WheelerHiddo J Lambers HeerspinkAndrew BriggsKlas BergenheimJuan Jose Garcia SanchezPublished in: Clinical journal of the American Society of Nephrology : CJASN (2022)
Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD), NCT03036150.